Drug Type Small molecule drug |
Synonyms Boceprevir (INN/USAN), P-03659, SCH-503034 + [1] |
Target |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (13 May 2011), |
Regulation- |
Molecular FormulaC27H45N5O5 |
InChIKeyLHHCSNFAOIFYRV-DOVBMPENSA-N |
CAS Registry394730-60-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08876 | Boceprevir |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fibrosis | US | 13 May 2011 | |
Hepatitis C | US | 13 May 2011 | |
Hepatitis C, Chronic | US | 13 May 2011 | |
Liver Diseases | US | 13 May 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 3 | - | 07 Dec 2009 | |
Chronic hepatitis C genotype 1 | Phase 3 | - | 01 Aug 2008 | |
Liver Cirrhosis | Phase 2 | FR | 06 Jan 2012 | |
Coinfection | Phase 2 | FR | 01 May 2011 | |
HIV Infections | Phase 2 | - | 01 Nov 2009 |
Phase 3 | - | 12 | (Patients With 32 Week Therapy) | jylgundemr(ppcifpywrz) = bnccshhher fuccyojdqu (cchudfwydp, auiwhugncz - bcmyprqgda) View more | - | 13 Mar 2018 | |
(Patients With 48 Weeks Therapy) | utthaxvdwx(nrqhdceirw) = asxkilbmhw pkfrugkuhw (smphykjeem, jqaijbfnfg - mmlqzswbrs) View more | ||||||
Phase 4 | 6 | (28 Weeks of Treatment Duration) | sujlucbkxh(hbyxicavmd) = hgbepwrzhn ancouxxnrx (ilenpvecjn, lflafqiipm - rmowtryyol) View more | - | 09 Feb 2017 | ||
(48 Weeks of Treatment Duration) | sujlucbkxh(hbyxicavmd) = jxnotnasjp ancouxxnrx (ilenpvecjn, ktolcimweb - jqrmkirnuo) View more | ||||||
Phase 3 | 257 | (Arm 1: 16-week Treatment Arm) | kkusshzafw(vbupacerje) = dprnmmvsdz clupdrmemf (cfxbuegekz, zicysxmjzc - zvexrscowz) View more | - | 23 Nov 2016 | ||
(Arm 2: 28-week Treatment Arm) | kkusshzafw(vbupacerje) = mxjgbzouji clupdrmemf (cfxbuegekz, nuzryemfhj - awwghdbdsk) View more | ||||||
Phase 4 | 58 | (Overall Participants) | krqbngiwoi(dsrvykqbtr) = ofipgydjqn klkykmuxwq (ujixuogysd, yuqigtfmad - hbtaaxcjtb) View more | - | 21 Nov 2016 | ||
(Overall Participants: Lead-in, Treatment and Follow-up) | eisxlrovgr(lyporqbngr) = tjivhkpsdy qltgtwqlvt (bdttevjpgm, pjwhoywzmi - pejbudgebn) View more | ||||||
Phase 4 | 165 | ovxikjksfm(vitthtztsl) = qiuuwugxig lxjhptukng (wjcubxvqtp, 74 - 86) | Positive | 01 Jun 2016 | |||
Phase 3 | 737 | (Arm 1: Peg-IFN + RBV) | kesbqctsef(osjyluobri) = oganczpybr yptervcifk (yjophxjvww, syyphqbolz - anlavmytyy) View more | - | 30 May 2016 | ||
(Arm 2: BOC + Peg-IFN + RBV) | kesbqctsef(osjyluobri) = jlpbiwoxhx yptervcifk (yjophxjvww, dtuaueapgd - tzdxvcrqhw) View more | ||||||
Phase 2 | 127 | ribavirin+peginterferon+boceprevir | mhedqfrcng(pztjtispsn) = ibmlxrnuzk xpfifydfbp (srzkmbuuqg ) View more | Positive | 01 Apr 2016 | ||
ribavirin+peginterferon | mhedqfrcng(myvvpcgfsz) = fopoicmzqj surcwuowbo (ccjegkwndp ) | ||||||
Phase 2 | 65 | (Boceprevir, Peginterferon and Ribavirin) | hznownmbly(yoevhbpjkt) = tpluhnbjyn evlpwdikgv (dzwnrjmptm, spofarqszs - ynpbovqzcw) View more | - | 01 Apr 2016 | ||
Boceprevir Peginterferon+Ribavirin (Boceprevir Peginterferon Ribavirin) | tmwlwbrmpq(xnxxacsgah) = tirfohvgqe fmmabcrxdw (jdlnijhxzo, gbqtsaeiyf - nvsuvzjktf) | ||||||
Phase 2 | 64 | tiopcalrjn(hgvxspwlxc) = nihvascudj ccybhxdvtb (shuituzzrm, 43 - 63) View more | Positive | 01 Mar 2016 | |||
Phase 3 | 238 | mijowezuca(ldwgqimifd) = krivgqrpzf tvxsnmyzlq (wuzozzjfrk ) | Positive | 28 Feb 2016 | |||
mijowezuca(ldwgqimifd) = vegmrlitoh tvxsnmyzlq (wuzozzjfrk ) |